SCHEMBL8901803

SCHEMBL8901803

CCC1OC(C(=O)O)CC2=C1C(=O)c1c(c(O)c3ccccc3c1OC(C)=O)C2=O

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 1/20 0.35
EPHX2 P34913 1/20 0.33
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HTT P42858 3/20 0.32
MAPT P10636 2/20 0.32
TP53 P04637 1/20 0.32
GAA P10253 1/20 0.32
HSD17B10 Q99714 1/20 0.32
DNMT3B Q9UBC3 1/20 0.31
HSP90AA1 P07900 1/20 0.31
PAX8 Q06710 1/20 0.31
PDE4A P27815 1/20 0.31
PDE4B Q07343 1/20 0.31
PDE4C Q08493 1/20 0.31
PDE4D Q08499 1/20 0.31
POLB P06746 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8903434 1.00 AKT1 (0.35) AKT1EPHX2KDM4EALDH1A1SMN1; SMN2
SCHEMBL8903882 0.95 AKT1 (0.36) AKT1KDM4EALDH1A1SMN1; SMN2HTT
SCHEMBL8902846 0.83 AKT1 (0.33) AKT1KDM4EALDH1A1SMN1; SMN2MAPT
SCHEMBL8902603 0.83 AKT1 (0.36) AKT1KDM4EALDH1A1SMN1; SMN2MAPT
SCHEMBL9755762 0.81 HTT (0.34) EPHX2KDM4EALDH1A1SMN1; SMN2HTT
SCHEMBL9755783 0.80 HTT (0.36) EPHX2KDM4EALDH1A1SMN1; SMN2HTT
SCHEMBL8901515 0.78 AKT1 (0.41) AKT1KDM4ESMN1; SMN2DNMT3BHSP90AA1
SCHEMBL8902124 0.75 HTT (0.36) EPHX2KDM4EALDH1A1SMN1; SMN2HTT
SCHEMBL9755777 0.75 HTT (0.36) EPHX2KDM4EALDH1A1SMN1; SMN2HTT
SCHEMBL8901690 0.75 HTT (0.36) EPHX2KDM4EALDH1A1SMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5593970-A ANTITUMOR AND ANTCARCINOGENIC AGENTS; TRETMENT OF CANCEROUS BONE MARROW BEFORE REGRAFTING BIOCHEM PHARMA INC. (CA) 1997-01-14 US disclosed